Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

August 2022

Venous Thromboembolism Risk with Janus Kinase Inhibitors: Is it a Class Wide Effect? (Editorial)

Expert Opin Drug Saf. 2022. doi: 10.1080/14740338.2022.2100343

Jubber A,

Woodward J,

Hasan T,

Moorthy A

It is too early to conclude that the second-generation JAK inhibitors have a lower VTE risk and caution in patients with VTE risk factors is required.

Keywords:

JAK,
Safety,
Thrombosis,
Review